

# Françoise Stanke-Labesque

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4618683/publications.pdf>

Version: 2024-02-01

45  
papers

1,232  
citations

448610

19  
h-index

445137

33  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1795  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization. <i>Journal of Clinical Medicine</i> , 2022, 11, 91.	1.0	2
2	COVID-19 lockdowns and incidence of psychoactive substance exposure according to age and sex. <i>Clinical Toxicology</i> , 2022, 60, 596-601.	0.8	3
3	Implementation of a Vancomycin Dose-Optimization Protocol in Neonates: Impact on Vancomycin Exposure, Biological Parameters, and Clinical Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0219121.	1.4	2
4	Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 427-435.	1.1	4
5	Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2534-2541.	1.1	17
6	Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. <i>Clinical Biochemistry</i> , 2021, 87, 60-66.	0.8	11
7	Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. <i>Scientific Reports</i> , 2021, 11, 3739.	1.6	4
8	Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1090-1099.	1.0	5
9	A simple and easy-to-perform liquid chromatography-tandem mass spectrometry method for the quantification of tacrolimus and its metabolites in human whole blood. Application to the determination of metabolic ratios in kidney transplant patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1173, 122698.	1.2	3
10	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021, 10, 2089.	1.0	14
11	Homicidal poisoning series in a nursing home: retrospective toxicological investigations in bone marrow and hair. <i>International Journal of Legal Medicine</i> , 2021, , 1.	1.2	1
12	Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?. <i>Pharmaceutics</i> , 2021, 13, 1960.	2.0	2
13	The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-to-Dose Ratio on Death-censored Graft Survival. <i>Transplantation</i> , 2020, 104, 1263-1271.	0.5	39
14	Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. , 2020, 215, 107627.		102
15	Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1888-1891.	1.1	11
16	Inflammation is a potential risk factor of voriconazole overdose in hematological patients. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 232-238.	1.0	32
17	A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. <i>Analytica Chimica Acta</i> , 2019, 1067, 63-70.	2.6	44
18	New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 722-728.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 417-424.	1.0	23
20	Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea?. , 2018, 186, 45-59.		7
21	Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome. <i>Pharmacological Research</i> , 2018, 134, 311-319.	3.1	14
22	Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations. <i>Pharmacogenomics</i> , 2017, 18, 1119-1123.	0.6	21
23	Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 1195-1205.	1.9	30
24	A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 221-222.	1.1	6
25	Could the thromboxane A2 pathway be a therapeutic target for the treatment of obstructive sleep apnea-induced atherosclerosis?. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 121, 97-104.	1.0	4
26	Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2305-2314.	1.4	56
27	Obstructive sleep apnoea and cardiovascular calcification. <i>Thorax</i> , 2015, 70, 815-816.	2.7	2
28	Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	1.4	23
29	Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. <i>Cardiovascular Research</i> , 2014, 101, 187-193.	1.8	31
30	Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2014, 91, 111-117.	1.0	19
31	Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 919-920, 1-9.	1.2	62
32	Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. <i>European Respiratory Journal</i> , 2013, 42, 404-413.	3.1	43
33	Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. <i>Journal of Lipid Research</i> , 2012, 53, 1944-1951.	2.0	34
34	Ribavirin therapeutic drug monitoring: why, when and how?. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 401-406.	1.0	7
35	Haemodialysis reduces raltegravir plasma concentrations. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 201-202.	1.4	1
36	Cardiovascular Consequences of Sleep-Disordered Breathing: Contribution of Animal Models to Understanding of the Human Disease. <i>ILAR Journal</i> , 2009, 50, 262-281.	1.8	109

#	ARTICLE	IF	CITATIONS
37	Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography–electrospray tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3734-3738.	1.2	12
38	Increased urinary leukotriene E4 excretion in obstructive sleep apnea: Effects of obesity and hypoxia. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 364-370.e2.	1.5	52
39	Urinary leukotriene E4 excretion: A biomarker of inflammatory bowel disease activity. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 769-774.	0.9	38
40	Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 179-195.	1.1	61
41	Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers. <i>British Journal of Nutrition</i> , 2008, 100, 829-833.	1.2	17
42	Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat. <i>Respiratory Physiology and Neurobiology</i> , 2006, 150, 278-286.	0.7	43
43	Urinary leukotriene E4 excretion is increased in type 1 diabetic patients. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 78, 291-299.	1.0	24
44	2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. <i>Cardiovascular Research</i> , 2004, 63, 155-160.	1.8	27
45	Increased Lipid Peroxidation in Patients with Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1038-1042.	2.5	162